bioLive is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Epidemiology is a core skill for biopharmaceutical companies. Being able to identify an area of unmet medical need helps guide R&D strategy and, ultimately, is what shapes drug pipelines.
It is also an important metric for bioprocessing technology suppliers. For such companies, disease monitoring is one of multiple factors used in sales forecasting and resource allocation.
Conor McKechnie, Chief Marketing Officer, GE Healthcare Life Sciences told us, “Modelling and predicting market demand for our current, planned and future products and services, is complex.
“Given the subsequent business strategy and capital allocation decisions, GE Life Sciences uses a very broad and constantly evolving series of data sources.”
GE does not disclose specific details of how it monitors markets, however, McKechnie confirmed that epidemiology is taken into consideration along with a number of other factors.
“These [GE’s market analysis metrics] include anything from macro socio-economic trends, disease epidemiology, national and transnational governmental investment strategies.”
He added that related metrics such as emerging areas of medical research as well as things venture capital activity, Government support for research and customer intelligence are also factored into decision making.
“Combining this myriad of constantly changing data and insight with, most importantly, a very clear understanding of our customers’ needs helps us reach the best decisions for our customers and our business.”
Biopharmaceutical product pipelines are also an important consideration when assessing markets according to Karen Tiano, company spokesperson, the Life Science business of Merck.
“We have a multi-step process. We look at the drug pipeline to understand what drugs are coming online, and we look at the commercial and development success — how they get to market, and once they get there, what the uptake is. At that point, we know roughly what the big molecules are.
She added that, “We have an internal model to figure out how much demand that actually means in terms of volume of drugs being manufactured. We then determine the specific demands for us for different types of products, whether it be consumables, instruments, systems or services in order to supply them.”
Looking at drug pipelines and products rather than clinical research is appropriate for the bioprocessing sector says Eric Langer, BioPlan Associates’ president and managing partner.
“Since single use systems (SUS) and bioprocessing devices are really not able to affect clinical outcomes – for example an RA biologic could be manufactured with the same equipment as a cancer therapeutic - these companies probably monitor the pipeline more than which clinical area is growing vs others.
He also told us that, “Monitoring pipeline could be an indication of future demand for alternative technologies. Similarly, biosimilars in the pipeline can be monitored, but these are more commercial decisions rather than directly bioprocessing-related.”
Bioprocessing technology suppliers also take IP laws into consideration before deciding how they will approach a market according to Dr Ross Cummings, senior associate patent attorney at Gill, Jennings & Every LLP.
He told us, “The IP landscape is certainly something that any technology company looking to enter a market should be aware of. This can most obviously help avoid stepping on others’ toes by identifying others’ rights and assessing the risk of infringing such rights.
“This can also be a useful exercise to assess the state of the art and identify potential competitors, partners and suppliers” Cummings said.